$13.820
-0.312 (-2.26%)Al cierre
Noticias de MGTX
Eventos de MGTX
Company Reports Q2 Revenue of $321.43M, Beating Consensus
Reports Q2 revenue $321.43M, consensus $10.45M. The company said, "Service revenue was $11.9 million for the three months ended June 30, 2026, compared to nil for the three months ended June 30, 2025. The increase of $11.9 million was due to revenue recognized for the contract manufacturing services provided to Lilly under the Lilly collaboration agreement and related agreements. Service revenue - related party was $104.9 million for the three months ended June 30, 2026, compared to $3.7 million for the three months ended June 30, 2025. The increase of $101.2 million was due to the release of deferred revenue from the termination of the original asset purchase agreement and supply agreement with J&J and the development and transition services provided to Reogen Limited, formerly known as Hologen Neuro AI Limited, under the Hologen collaboration agreement and related agreements, which was partially offset by decreased activity of PPQ services under the original asset purchase agreement and related agreements with J&J as the work was substantially completed in the first half of 2025. License revenue - related party was $204.6 million for the three months ended June 30, 2026, compared to nil for the three months ended June 30, 2025. The increase of $204.6 million was due to revenue recognized for the licenses granted to Reogen for the AAV-GAD and AAV-BDNF programs and the AAV-GAD delivery device."
MeiraGTx Enters $400M Investment Agreement with Oberland Capital
MeiraGTx announced that it has entered into an agreement with Oberland Capital for an investment of up to $400M in the company, including up to $375M in non-dilutive capital for capped royalty payments on certain products and up to $25M in equity. The investment by Oberland Capital provides for up to $400M in total capital to MeiraGTx, including up to $375M in non-dilutive royalty funding and up to $25M in equity, as follows: the initial $135M funded includes $125M in exchange for low single-digit royalties on the included products, and a $10M equity investment; an additional $50M will be available at the company's option tied to AAV2-hAQP1 positive data readouts from the Phase 2 AQUAx2 study in 2027; an additional $50M will be available at the company's option tied to regulatory approval of bota-vec in 2027; an additional $50M will be available at the company's option tied to regulatory approval of AAV2-hAQP1 in 2028; a further $100M is available upon mutual agreement for new products or business development and Oberland Capital has the right to purchase an additional $15M in equity in MeiraGTx. The agreement with Oberland Capital includes flexible provisions for potential change of control, with the ability for the Company to buy back the entire funded royalty note at any time by paying certain specified amounts. Royalty payments are capped at a multiple of the amounts funded.
MeiraGTx Reports Q1 Revenue of $293,000
Reports Q1 revenue $293,000 vs. $1.93M last year. "Our achievements in the first few months of 2026 have materially strengthened MeiraGTx - we are now in a position to file for potential approval and launch two wholly-owned therapies in the next 2 years," said Alexandria Forbes, president and chief executive officer of MeiraGTx. "The compelling three-year durability data from our AAV2-hAQP1 Phase 1 study continue to demonstrate disease-modifying benefit following a simple one-time treatment of patients with moderate to severe persistent radiation-induced xerostomia, an otherwise debilitating life-long condition. The recent receipt of Breakthrough Therapy Designation for this program reinforces the strength of the data and the potential for an expedited development and regulatory pathway."
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.